“€‡   €Œ €„€, † †‚€ € („, ˜€Œ),  †‚  +7 (495) 649-81-80 , €‹ +380 (94) 710-59-15 ‚€ “ +(972) 4830-53-51 €“  8:00 18:00.

˜‚‚ƒ‚ € €

‚€ ’€

ž šž• •™ š›•ž—?

›‡ €ƒ

‹ € (Multiple Sclerosis M.S.) - ‚Œ †‚€Œ € ‚‹ - ‡.

‘Œ ‚ - € ‚ - . œ - € ‚Œ, €ƒŽ‰ €‹ ‡ ‰‰Ž‰ …, †, ‰‰Ž‰ ‚€‡ €. Ÿ€ ‡ €‚ €ƒˆ €… € ƒŒ €‡ €† ‚ ‡ €‡‹ ƒ‡‚ €.

Ÿ€ ‡ €‚ Ž € €, ‚ ‚Œ €€‚€Ž ‡  €ƒ†  †‚€Œ € ‚.

šž ‘ž›•• •œ š›•ž—žœ?

š €, €‹ € Ž‚ €‹ Ž €‚. ’€‹, €, Œ €‚ €‚ ƒ 20 40 , ‚ €‚Œ  40 ‚, ‚ ‚ €‚.

‘Ž‚ ‡‰  ‰‹ (‚ˆ ‡ € ƒ‡ ‰ ‚‚ 1:3). €‚€‚Œ  ‚ ‚ ‚ ‚‡… €„‡… „‚€: Œ €€‚€ € ‹…† € •€‹ € €.

›‡ €ƒ

˜œŸžœ —‘ž›•’˜

€‹… Œ‹… €‚ -€ƒ. š‡ € „ƒ†Œ‹ €ƒˆ ‚ ‚ €  ƒ‡‚ €… € ‚‹ Ž‡Ž‚: ‰ƒ‰ "" €‡‹… €, ‚Œ ‡‚ (€ƒ ), ‚ €‚ ‚ƒ€ €‚, … € "" €, €ƒˆ ‚€ ‚‚‹ ‚€ € ‚.. ˜ ‹ ‚… ‚ €‚ ‚Œ‚, - ‚. ‹ €‚ƒ … ‚€‚ ƒ €‹… Œ‹… €‡‹; €‡‹ ƒ ‚ Œ ‚ ‚ ‚ €‚ .

›‡ €ƒ

••˜• ‘ž›•—˜

€ƒ € €‚Œ €‚ ‚ , €‹ €. ž ‚ ‹‚Œ ‡Œ ‹€‚Œ €‡… €‚ƒ…, ƒ‚ ‹‚Œ ‚‹ €€€ƒŽ‰ ‚‹, €‰ €ƒˆŽ ‚.

‚€ ‚€ƒ‚Œ €€ ‚‡ , ‹‚Œ 4 ‹… €‚:

• Ÿ€€ ƒ 2/3 Œ‹… Œ €‚ €‹… ‚… €‚ƒ € €† (Relapsing - Remitting). Ÿ€‚ƒ (Relapse) - ‚ € € … ‚, ‚…  €, ‚€ƒ‚ €†, ‰ƒ‰  ‡‚, ‚€  ‚€ ‚‚‹ ‚€ €. (‚ ‚‹ €Ž‚ ‚Œ‚ ‡‚ €ƒ  €ƒ). Ÿ€† €† (Remission) €‚, €, ‚ Œ… Œ… Œ. Ÿ ƒƒ‡ˆ ‚ ƒ‰‚ƒ‚, €, € € (€†), ‰ Œ † ‚. ’ € € (€†) ‚‹ €Ž‚, ƒ †‚ ‚ €‡ ‚.
• ‚ ‚€‡ €€€ (Secondary Progressive). Ÿ Œ… ‚€ ƒ ‚€‹… †‚ Œ ‚ƒ‚ ‚€ ‚ €€€.  ‚ ‚  ‚€ €† €…‚, Œ‹ ƒ‚ ‚€‚Œ ‚‹ Ž‰ „ƒ†Œ‹ €ƒˆ.
• Ÿ€‡ €€€ƒŽ‰ (Primary Progressive). Ÿ€€ ƒ 15% Œ‹… €‚ €€€ƒ‚   ‡, ‡‚ ‹€‹… € ‚€.
• € ‚‡ (Benign) €‚ €€ ƒ 15% -20% Œ‹…. ‚… Œ‹… ‚ €‚Œ ‚€, ƒŽ‰ € ‚€ ‚€‚ ‡€ 10 ‚ .

’ƒ ‚, ‡‚ ƒ €‹… Ž Œ €‚ -€ƒ, ‚Œ ‹‹ …€‚€ €€€‚Œ  ƒ Œ  ‹… …€‚€ €€€  ƒ €ƒ Œ.

›‡ €ƒ

”˜“ž˜š ‘ž›•—˜

Ÿ€† ‚ € € ‹‚ ‚‡ ‚€ , ‰ †‚, „‡   „ƒ†€ € ‚‹.

’  ‹ €†ƒ€ ‚ €‚ ‚Œ‹ , ‚ :

•  ‚  (CSF), †Œ ‚€ - ‹ € ‚Œ‹… €† € ‚
• ‚‹ ‚€ (MRI) ‡. ž ‹‚ € ‚ ‡ , … ‡‚ Š. ž MRI -  ‚ , ‚ ‚ † ‚ ‚‚ .
• € ‚† ƒ € (VEP) ƒ… (BERA) €‚  € €† € ‚‹ €‚Œ‹ ƒ‹ ‹, &129;€‹ .

š›˜˜•š˜• Ÿž’›•˜ —‘ž›•’˜

ƒ‰‚ƒ‚ Œˆ €‡ € ‚ € €. €Œ ‚‚  ƒ €‹… Œ‹… €‡, €‹ ‚‹, ‚€Ž‰ ƒ Œ, ƒ‚ ‰ €‚Œ ƒ €ƒ Œ.

›‡ €ƒ

Ÿ˜˜ —‘ž›•’˜

Ÿ€‡‹  € € … € ‹‹  ‚€‚ŒŽ. ’‚  ‚,  … ‚ ƒ‹Ž‚ ‚, ‡‚ €‡Œ,  €‚‚, ‚ ‡‚ Œ… „‚€: € ‚‡ €€‚ „‚€ ˆ €‹, ‚… ‰ ƒ‚ €ƒ „† / €ƒˆ €Œ €† € .

‡‚ ƒ‹… „‚€ €‚,  ‚, €ƒˆŽ „ƒ†€ ƒ ‚‹ ‚ƒ, ‡‚ ‡‚ ‚‚Œ €ƒŽ ‚ƒ. Ÿ ‚ƒ, ‚ €…‚ € €ƒ… ‚ƒ‹… … (€€, € …€ ‚ … ƒ‚), €ƒˆ‚ €‚ ƒ ‚‹, ‚€ ‡‚ ‚‚Œ  €, - ‚‡ ‚ ‚ €…‚ € € €. Ÿ€ ‚ ƒ ‚ ˆ ‚ƒ‚ ƒŽ ‡ƒ †‚€Œ € ‚‹. ˜ƒ ‚, ‚€ €‚Œ "" ‚Œ  €‹ ‚ - ‚, €ƒ‹ €‹ - ˆ ‡‚ ‚‚Œ , € ‚, €ˆ €. ƒŒ‚‚ ‚ ‚€ ‚ ‚Œ‹ €†, €Ž‰ €‰, ƒ , €ƒˆ €‡ €‹… ƒŒ.

š €,  €‹… €‚ƒ Ž‚ ‚ ‹€, € ƒ‡ ‡‚ €‚ƒ ƒ‰‚ƒ‚ ‚Œ ‹€  ‚€†‚Œ €‡ „„‚.

‚ „‚‹ €‚Ž‚  ƒ  ‡, †Œ ‚€ -€‚€‚‚Œ €‚ƒ‹ ‚‚Œ €€€ƒŽ‰ €†, €Ž‰ €ƒŽ ‚ƒ.

‘••œ•ž ˜ •™ š›•ž—

… ‰ €ƒ‚ €‹ € ‚‚ €, €Ž‚ ‚Œ ŒŽ …‚‚ €‚Œ €.

˜ ‹Ž‚ - €‚Œ ƒƒƒ‚ ‚‡ -€‚: € €‚ ‡‚ €‚ƒ ƒ ‰, Œ‹… €‹ €, ƒŒˆ‚,  € € ‚ ‚‚ ‚, ‹ €‚.

›‡ €ƒ

Ÿ˜˜• ˜ •™ š›•ž—

” ˆ  ƒ‡ , ‡‚ ‚  ‚ ‚ €‚ € €. ƒ‚ Ž‚Œ €Œ‹ € ‚ - €† ‹‚Œ €€‹.

† ‚Ž Œ‹… €‹ €: ƒ‚ ‚Œ   ƒ‚Œ €. ˜‹‚‡‹  ‚ €‚ ˆ €ƒ ‹‚Œ ‚€ƒ‚ €.

‘Œ‹, ‚€Ž‰ €, €ƒ‚ ƒ‚€‚Œ Œˆ ‰, ‚ ‚‚Œ‹ , Ž‰ €‚Œ €‚ƒ ˆ‡. ’ (‚‡‚) €‚ €‚…,  - ƒ€ €‚, „€ƒ‚… ‰…, ‡‰ €ƒ, € ‹….

’ Ž ‚€ ‚‹, € ‚ … ‚Œ €† …‹ ‚. ƒ‚ ‚Œ ƒ€ ‚ ’12, ƒ‡ „†‚ - ‚Œ .

’ ‚‚‚Œ: €‹‚ €‹… ‚ ‚ €‡‚Œ €.  ƒ‚ €† €‡ ‚ €‚Œ ‚‹ €‹ ‡‚ ƒ‚ ‰.

›••‘• Ÿž•” Ÿ˜ •žœ š›•ž—•

‚€ ‚, ‡‚ ‰ ‹ ‹ €„‚ ‡,  ‹ ‚ƒ‚ Œˆ €€ ‚ €‚ ‚ ‡ € €.

, ‚€‹ ‚‚ € € ‡:

•  ‡‚ ‚€‚‹ €‚ƒ
• ‚ €‚ „ƒ†Œ €
• ‡ ‚ ƒ‰‚ƒŽ‰… „ƒ†Œ‹… €

š  ‹ˆ, ‡‚Œ ‡‚Œ €‚ƒ €…‚ ‚,  ‡.

’ ƒ‡ ‚€, ‚ €‚ƒ, ‚ ƒ…ƒˆ €, ‹  €‚Œ €, ‚€ƒ‚ €† …Œ, €‚  ‚ €ƒ‚€‚ ‡‚ ƒ‚€ „ƒ ‚€ ‚‡ Œ… ,  ‚ - € ‚€ ‚‚,  ‚‹  €. Œ ‚ ‡ - ƒ ‚‹, ‚€ €€Œ …‚ ˆ ‚ ‚. ”€ƒ ‹ ‚‚‡ ‡ €Ž‚  ‚ ‹ˆ‡‹… , ‰ƒ‰ "" ‚Œ‹… ƒ‡‚ ‚, ƒ‚‚, ‚€ƒ‚ ‚€ ‚‚‹ ‚€ € ‚..

’  ‹ ‚ƒ‚ €Œ‹ €€ „€ ‡ €, €‡ €‡Œ ‚ ‚ ‚ , ‚€‹ …€‚€ƒ‚ ‚‹ €‚ƒ. ƒ‹  ˆ€ˆ‚‹ ‡ €‚‹ ‚€ „„‚‚Œ Œ… ‹… €‚, ‚€‹ ‹ ƒ‚€‹ ‡‚ €„‚‡ ‡ .

œ‚€‚ €…€ ˜€ ƒ‚€ € 4-… €€‚  ‡ ‚ ‚ , ‚€‹ …€‚€ƒ‚ ‚‹ €‚ƒ. ˜… ƒ‚€  ‚Œ‚ ƒ‰‚ „„‚‚ ƒ Œ ‚: ) ‡‚Œ  ‡‚ €‚ƒ; ) ƒ‰‚  ‚ ƒ…ƒˆ ‚.

’ ‡ €€‚, ƒ‚€‹… €Ž, …‚ ‚€ …‹… €€‚ €ƒ‹ ‚-‚€„€ €€‚  (ž-1). Ÿ€€‚ ‚„€ (Betaferon, ‚€„€-‚ €“ 1b) ‹ €‹ €€‚, ˆ Ž „„‚‚Œ. ›‡ ‹‚ Š†, € .

’‚€ €€‚, ˆ Ž „„‚‚Œ ƒ‚€‹ €Ž ‡‚ €„‚‡ ‡, - ‚  (Acetate Glatiramer Copaxone ž-1). ‚‚ €€‚, €€‚‹ ˜€, ‚ ‚ , .

” €ƒ… €€‚ €ƒ‹ ‚€„€ - ‚  (Avonex), ‹ ƒ‚€‹ˆ‡ € Ž, €„ (REBIF), ‹ 3 € Ž. ‚ €€‚‹ ‚ €‹  ‡ Œ‹… €‹ €, €Ž‰ €‚ƒ. Ÿ€€‚‹ €‚‹ ˜€.

 ‡‹ €ˆ€‹ ‹‚ ‚-‚€„€, ‚€‹ ‹ € Œ‹… €‹ € €€€ƒŽ‰ ‚, ‹ , ‡‚  ‚ €ƒ‹ Œ‹… ‡ ‚ „„‚.

’ ˆ ƒƒ‰ ‹ ‡‚Œ €€ ‡ Œ‹… €‹ €.

• ž‚ ‡ €‚Œ €€ ‚ ‡, †Œ ‚€‹… - €… ‚ Š† ( ‚ €‚ ) ‚‚, ‡‚ €‚ ƒ‰‚ ‡ Œ‹, ƒƒ‡ˆ‚ … ‡‚ .
• ž‚ ‡ ‡… €‚ - € "€‚‹… ‚": † €‡‹… ‚ ‡ ‚‚‚  ‚ …€‚€  -  Œ‹… …€‡ „€ „€, …€‚€ƒŽ‰ €‚ƒ. , €€, €‚‹ ‚ ƒƒ‚ Ž‡‚Œ €‚, †Œ ‚€‹… - ‚Œ €† ƒ, €‚, †Œ ‚€‹… - ‚ €ƒˆ ‡.

—š›•˜•

’ƒ ‚, ‡‚ ƒ €‹… Ž Œ €‚‚ -€ƒ, ‚Œ ‹‹ …€‚€ €€€ ƒ Œ  ‹… …€‚€ ƒ €ƒ Œ. ƒ‚ ‚Œ, ‡‚:

• ‚Œ Œ‹… ‚€‚ ŒŽ „€, ‚€ €‚ €‡Ž ‚.
• ‚€‹… Œ‹… €‡ ‚ ‚ ‹‚Œ €‹.
• ‚€‹… Œ‹… €‚ ‹ €‚‚.
• Œ ƒ Œˆ ‡‚ Œ‹… €‹ € ƒ‚ €‚Œ ‚‹ „ƒ†Œ‹ €ƒˆ.

, € €€ƒ †‹, €‚‚ €‚‚Œ ‚, ‡‚ …‰ ‚ ‡ ‡‚, ‚ €‚€‚‚ ‚… €ƒˆ.